Arturo Molina, M.D., M.S., F.A.C.P., serves as the Chief Medical Officer at Protagonist Therapeutics Inc., a biopharmaceutical company focused on developing peptide-based drugs for various diseases. Dr. Molina brings a wealth of experience to his role, having spent over two decades in the field of hematology and oncology. He holds a medical degree from the University of California, San Francisco, and a Master's degree in Clinical Research from the same institution. Additionally, he is a Fellow of the American College of Physicians, reflecting his commitment to excellence in the medical field. Throughout his career, Dr. Molina has made significant contributions to the development of novel therapies for cancer and other serious diseases. He has held leadership positions at several prominent pharmaceutical companies, including Genentech and Pharmacyclics, where he played a key role in the development and commercialization of groundbreaking treatments such as ibrutinib for chronic lymphocytic leukemia. His research has been published in numerous peer-reviewed journals, and he has been an invited speaker at international conferences, sharing his insights on the latest advancements in hematology and oncology. As Chief Medical Officer at Protagonist Therapeutics, Dr. Molina oversees the clinical development of the company's pipeline, which includes innovative treatments for inflammatory bowel disease and rare blood disorders. His strategic vision and deep understanding of the drug development process have been instrumental in advancing Protagonist's mission to bring transformative therapies to patients in need. Under his leadership, the company has made significant progress in its clinical trials, bringing hope to patients and families affected by these challenging conditions.